Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | RESONATE-2: Ibrutinib for CLL 5-year follow-up

Alessandra Tedeschi, MD, Niguarda Cancer Center, Milan, Italy, gives an update on the RESONATE-2 study (NCT01722487) looking at the use of ibrutinib in patients with chronic lymphocytic leukemia (CLL) who are aged ≥65 years. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.